Tango Therapeutics: Q3 Earnings Insights
Portfolio Pulse from Benzinga Insights
Tango Therapeutics (NASDAQ:TNGX) reported Q3 earnings, beating estimated earnings by 32.35% with an EPS of $-0.23 versus an estimate of $-0.34. Revenue was up $3.81 million from the same period last year. Last quarter, the company beat EPS by $0.11, which was followed by an 11.34% increase in the share price the next day.
November 08, 2023 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tango Therapeutics reported better than expected Q3 earnings, which could lead to a positive impact on its share price, as seen in the previous quarter.
Tango Therapeutics reported a 32.35% beat on estimated earnings, which is a strong positive signal for investors. In the previous quarter, a similar beat led to an 11.34% increase in the share price the next day. This pattern suggests a potential positive impact on the share price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100